CSL Seqirus completes its 2026/27 influenza vaccine production cycle, bolstering U.S. supply chains as the company fulfills the bulk of its seasonal customer orders.
CSL Seqirus, a business of CSL, completed its 2026/27 influenza vaccine manufacturing campaign and expanded U.S. availability, a routine operational milestone with no material financial impact disclosed.
CSL Seqirus has successfully concluded its 2026/27 influenza vaccine manufacturing campaign, ensuring expanded availability across the United States. The company confirmed that the majority of customer orders have been fulfilled as it prepares for the upcoming peak immunization season.
CSL Seqirus has completed its manufacturing campaign and has expanded vaccine availability throughout the United States, with most customer orders already fulfilled.